Drugs, uses and methods

A technology of medicaments and compositions, applied in the field of compositions for the treatment of refractory cancer and/or recurrent cancer, capable of solving problems such as lack of therapeutic antibody therapy

Active Publication Date: 2022-04-26
BIOINVENT INT AB
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Unfortunately, effective therapeutic antibody treatments for relapsed and / or refractory cancers are still lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drugs, uses and methods
  • Drugs, uses and methods
  • Drugs, uses and methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0664] Example 1: Actual data collection

[0665] summary

[0666] Therapeutic antibodies have transformed cancer treatment, unlocking new mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and patients display either intrinsic or acquired resistance. Here, we demonstrate the therapeutic potential of targeting and blocking human (h)FcγRIIB, a receptor implicated in immune cell desensitization and tumor cell resistance to antibody drugs. An FcγRIIB-blocking antibody prevents internalization of the CD20-specific antibody rituximab, thereby maximizing cell surface accessibility and immune effector cell-mediated antitumor activity in vitro and in vivo. In a fully isogenic hFcγRIIB Tg mouse model, hFcγRIIB mAb enhanced B cell depletion by rituximab. In a mouse model assessing depletion of human chronic lymphocytic leukemia (CLL) tumor cells from a resistance-prone stromal compartment, coadministration with rituximab improved on-target and compl...

Embodiment 2

[0895] Example 2: Exemplary Pharmaceutical Formulations

[0896] Although it is possible for the composition, and / or antibody, and / or agent, and / or drug of the invention to be administered alone, it is preferred that it be presented as a pharmaceutical formulation together with one or more acceptable carriers. The one or more carriers must be "acceptable" in the sense of being compatible with the composition, and / or antibody, and / or medicament, and / or drug of the invention and not deleterious to the recipient thereof. Typically, the carrier will be sterile and pyrogen-free water or saline.

[0897] The following examples illustrate medicaments and pharmaceutical compositions according to the invention, wherein the active ingredient is an antibody molecule and / or agent of the invention.

Embodiment A

[0898] Example A: Tablets

[0899]

[0900] Tablets are prepared from the above ingredients by wet granulation followed by compression.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention describes a composition for treating refractory cancer and / or recurrent cancer, said composition comprising antibody molecules and agents; and a method of treating refractory cancer and / or recurrent cancer, The methods include administering antibody molecules and agents. Kits comprising the antibody molecules and agents are also described.

Description

technical field [0001] The present invention relates to a composition for treating refractory cancer and / or recurrent cancer, said composition comprising an antibody molecule and a medicament. The invention also relates to a method of treating refractory cancer and / or relapsed cancer comprising administering an antibody molecule and an agent. Also described are kits comprising the antibody molecules and agents. Background technique [0002] Therapeutic antibodies have transformed cancer treatment, unlocking new mechanisms of action by engaging the immune system. For example, the mechanism by which antibodies can exert a therapeutic effect is through the recruitment of natural effector systems, such as cytotoxic cells (e.g., macrophages) and enzymes (e.g., complement), which then target the cells to which the antibody molecule binds to Stimulates the removal of cancer cells and other harmful cells. [0003] The CD20-specific monoclonal antibody (mAb) rituximab (rituximab) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C07K16/30A61K39/395A61P35/00
CPCC07K16/283C07K16/2887C07K16/2893C07K16/30A61K2039/55A61K2039/507C07K2317/73C07K2317/94C07K2317/92C07K2317/75C07K2317/732C07K2317/77C07K2317/76C07K2317/33C07K2317/21A61K9/0034A61K9/0048A61K47/02A61K47/10A61K47/12A61K9/0095A61K9/02A61K47/26A61K47/38A61K9/2018A61K9/2027A61K9/2054A61K9/2059A61K9/4858A61K9/4866A61P35/00A61P37/04A61P43/00A61K39/39558A61K2039/505C07K2317/56A61K39/395C07K16/28C07K2317/565
Inventor B·弗伦德修斯英格丽德·泰格L·玛藤松马克·克拉格阿里·鲁加尼安
Owner BIOINVENT INT AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap